Mitotech

Mitotech is a biotechnology company with the goal of developing and selling a series of innovative drugs based on novel bioactive compounds — mitochondrial-targeted antioxidants known as SkQ. SkQ1 acts on mitochondria at the cellular level through an innovative mechanism to treat dry eye syndrome. Unlike most current treatments that utilize anti-inflammatory mechanisms, SkQ1 targets and blocks oxidative stress reactions in the eye, not only alleviating ocular inflammation but also improving issues such as degeneration of ocular surface tissues and reduced tear quality. Dry eye syndrome is a chronic ophthalmic condition where patients experience ocular discomfort and inflammation due to damage to the eye's tear film. This damage may result from decreased tear production, imbalance in tear composition, or excessive tear evaporation. The ocular discomfort and pain caused by dry eye syndrome reduce patients' quality of life and lead to difficulties in activities like reading, driving, using computers, or performing other daily tasks. Currently, the primary traditional treatment for these patients involves the use of artificial tears, and clinical needs remain largely unmet.